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Abstract
Objective: To investigate whether there is a difference in the risk of asthma exacerbations 
between children with pre-existing asthma who receive live attenuated influenza vaccine (LAIV) 
compared with inactivated influenza vaccine (IIV).
Material and methods: We identified IIV and LAIV immunizations occurring between July 1, 
2007 and March 31, 2014 among Kaiser Permanente Northern California members aged 2 to <18 
years with a history of asthma, and subsequent asthma exacerbations seen in the inpatient or 
Emergency Department (ED) setting. We calculated the ratio of the odds (OR) of an exacerbation 
being in the risk interval (1–14 days) versus the comparison interval (29–42 days) following 
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immunization, separately for LAIV and IIV, and then examined whether the OR differed between 
children receiving LAIV and those receiving IIV (“difference-in-differences”).
Results: Among 387,633 immunizations, 85% were IIV and 15% were LAIV. Children getting 
LAIV vs. IIV were less likely to have “current or recent, persistent” asthma (25% vs. 47%), and 
more likely to have “remote history” of asthma (47% vs. 25%). Among IIV-vaccinated asthmatic 
children, the OR of an inpatient/ED asthma exacerbation was 0.97 (95% CI: 0.82–1.15). Among 
LAIV-vaccinated asthmatic children the OR was 0.38 (95% CI: 0.17–0.90). In the difference-in-
differences analysis, the odds of asthma exacerbation following LAIV were less than IIV (Ratio of 
ORs: 0.40, CI: 0.17–0.95, p value: 0.04).
Conclusion: Among children ≥2 years old with asthma, we found no increased risk of asthma 
exacerbation following LAIV or IIV, and a decreased risk following LAIV compared to IIV.
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1. Introduction
In 2003, a nasally-administered, live attenuated influenza vaccine (LAIV, FluMist; 
MedImmune, Gaithersburg, MD) was approved by the US Food and Drug Administration 
for persons 2 years through 49 years of age [1,2]. From the 2007–2008 influenza season 
through the 2015–2016 season, the Advisory Committee on Immunization Practices (ACIP) 
recommended the use of either LAIV or inactivated influenza vaccine (IIV) in healthy 
children and adolescents ≥2 years of age [3–7], but either recommended, or cautioned, 
against use of LAIV in children with asthma, depending on the age of the child [4,6,7].
Concerns about use of LAIV in asthmatic children were partly based on a pre-licensure 
randomized placebo-controlled safety trial that suggested increased wheezing following 
LAIV [8]. However, asthma was not one of that trial’s pre-specified endpoints, and this 
finding occurred in the context of >1500 statistical comparisons [8]. Subsequent evidence 
for increased asthma exacerbations among children older than 2 years of age receiving LAIV 
is limited. Another randomized trial comparing LAIV with IIV found non-significantly 
higher rates of hospitalization following LAIV among children 24–47 months old with a 
history of wheezing illness [9]. An open-label, non-randomized trial [10] found no increase 
in healthcare utilization attributed to respiratory illnesses in LAIV recipients, and two post-
licensure studies (which excluded LAIV-vaccinated children with asthma) also found no 
increase in respiratory events following LAIV [11,12].
Few studies have examined adverse outcomes following LAIV in children with asthma or 
related respiratory conditions. An open-label field trial among children with intermittent 
wheezing, found no increase in acute asthma exacerbations in the first two weeks after LAIV 
vaccination [13]. Two randomized trials, one among children with asthma [14] and one 
among children with history of recurrent respiratory tract infections [15], and two post-
marketing evaluations among children with asthma or recurrent wheezing [16,17], found no 
increase in adverse events among children receiving LAIV compared with IIV. A Cochrane 
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review concluded there was no difference in asthma exacerbations between vaccine types in 
children over 2 years of age, while acknowledging the number of patients on which that 
conclusion was based was small [18].
In 2016, the ACIP made an interim recommendation that health care providers in the U.S. 
not use LAIV in the upcoming influenza season, citing poor effectiveness [19]. Nevertheless, 
some providers may elect to use LAIV [19], it continues to be recommended outside the 
U.S. [20,21], and may again be recommended for use in the U.S. in future seasons. 
Therefore, the safety of LAIV use in children with asthma remains a concern.
The goal of this study was to investigate the safety of LAIV administered to children and 
adolescents with a history of asthma and to evaluate whether its safety profile varied 
according to asthma severity. We compared LAIV versus IIV with respect to asthma 
exacerbations and other adverse outcomes in children and adolescents with a history of 
asthma within Kaiser Permanente Northern California (KPNC).
2. Materials and methods
2.1. Setting
KPNC is a nonprofit, integrated health care delivery system that provides comprehensive 
health services to 3.5 million members. KPNC databases capture immunizations and 
inpatient, emergency department (ED), and outpatient diagnoses. Immunizations are 
provided at no additional cost to members and are almost all received within the system. 
This study was approved by the Kaiser Permanente Northern California Institutional Review 
Board.
2.2. Study population
We identified all IIV and LAIV immunizations between July 1, 2007 and March 31, 2014 
for KPNC members aged 2 through 17 years who were continuous KPNC members for two 
years prior to immunization (2009 Pandemic monovalent vaccines were not included). We 
retained immunizations for children with a history of asthma – those who received at least 
one International Classification of Diseases, 9th Revision, Clinical Modification (ICD9) 
diagnosis code for asthma (493.xx) any time prior to IIV/LAIV immunization. We included 
the same child over multiple seasons if they received immunizations in more than one 
season, and included children who received different vaccine types (IIV or LAIV) in 
successive seasons.
2.3. Classification by asthma severity
Children were classified into one of three groups at immunization: (1) “current or recent, 
persistent asthma”; (2) “current or recent, not persistent asthma”; (3) “remote history of 
asthma only”. Children had “current or recent, persistent asthma” if they met at least one of 
these criteria in the year prior to immunization:(1) Asthma principal diagnosis from an 
inpatient hospitalization or ED visit; (2) ≥3 outpatient visits accompanied by an asthma 
diagnosis; (3) ≥1 prescriptions for an anti-inflammatory medication (i.e., inhaled 
corticosteroids, oral steroids, methylxanthines, mast cell stabilizers, leukotriene modifiers, 
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and immunomodulators). Children had “current or recent, not persistent asthma” if they met 
at least one of these criteria during the two years prior to immunization: (1) Asthma 
principal diagnosis from an inpatient hospitalization or ED visit; (2) ≥1 outpatient visits 
accompanied by an asthma diagnosis; (3) ≥1 prescriptions for any asthma medication (anti-
inflammatory or beta2 agonist); (4) Did not meet criteria for “current or recent, persistent 
asthma”. Children not meeting the criteria above at the time of immunization had “remote 
history of asthma only”. A child’s asthma severity could change from one season to the next. 
We adapted the first two criteria from Wakefield and Cloutier [22] as proxies for asthma 
severity. Our criteria “current or recent, not persistent asthma” differs from the Wakefield 
and Cloutier criteria by looking back two-years rather than one, which allowed greater 
differentiation between it and “current or recent, persistent asthma”.
2.4. Adverse outcomes
The primary outcome was acute asthma exacerbation, defined as: (1) acute inpatient 
hospitalization or ED visit accompanied by a principal diagnosis of asthma; or (2) a chart-
confirmed outpatient asthma visit. We also identified all non-asthma outpatient visits as a 
“negative control”, since we did not expect such visits to vary between IIV and LAIV 
recipients. Secondary analyses assessed non-asthma adverse outcomes: afebrile seizure, 
Bell’s palsy, epistaxis, febrile seizure, fever, gastrointestinal disorders, migraine, otitis 
media, and sinusitis (Supplemental Table 1).
2.5. Medical record review: Validating outpatient asthma events
We reviewed charts for outpatient asthma visits to validate that the visits were for acute 
asthma exacerbations rather than routine asthma management or follow-up. We reviewed the 
medical records for all outpatient asthma visits during risk and comparison intervals 
following LAIV. These intervals were selected based on the literature or expert opinion. To 
compare risk for asthma exacerbation following LAIV versus IIV specifically among 
children with “remote history of asthma only” (who may have the lowest risk of asthma 
events), we also chart reviewed all post-IIV outpatient asthma visits for those children. 
Resource limitations precluded reviewing visits for IIV-vaccinated children with “current or 
recent, persistent” and “current or recent, not persistent” asthma.
2.6. Analyses
We used a case-centered, risk-interval, approach to evaluate the association between 
immunization and each outcome. The risk-interval aspect of our approach, which compares 
the odds of an event occurring in the risk interval versus the comparison interval, allows us 
to include only vaccinated individuals, thus reducing biases that might be introduced by 
including unvaccinated persons (who might differ from vaccinated persons in unmeasured 
ways) [27]. The case-centered aspect of our approach is similar to a stratified Cox 
proportional hazards model, but is much less computationally burdensome [23]. Like a Cox 
model, the case-centered approach can rigorously adjust for calendar time and reduce biases 
relating to temporal trends or seasonality. This approach has been described in detail [23] 
and been used in prior vaccine effectiveness and safety studies [24–27]. For each 
combination of vaccine (LAIV or IIV) and outcome (e.g., IP and ED asthma exacerbations), 
a logistic regression model was fit to a dataset consisting of one record for each outcome 
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event that occurred in either the risk or comparison interval. The dependent variable 
indicated whether or not the outcome occurred during the risk interval. The independent 
variable was based on the proportion of vaccinees that were in the risk interval on the 
calendar day of the case’s outcome event, among all vaccinees in the case’s age-sex stratum 
that were in either the risk or comparison interval on that date (age strata were defined in 
one-year increments). The logit of this proportion was included as an offset in an intercept-
only logistic regression model so that the fitted models yielded estimates of the ratio of the 
odds of an event being inside the risk interval versus the odds of an event being inside the 
comparison interval. In the absence of residual confounding, we interpret this difference in 
odds as attributable to the vaccine. In primary analyses of asthma exacerbation, the risk and 
comparison intervals were 1–14 days, and 29–42 days, after immunization, respectively.
We then examined whether the difference in the odds of an event being in the risk versus 
comparison interval differed between children vaccinated with LAIV versus IIV – i.e., we 
examined the “difference-in-differences”. We added to the model an independent variable 
indicating whether the child received LAIV or IIV. The exponentiated parameter estimate of 
this binary variable is a ratio of odds ratios and indicates how much more likely it is that the 
event occurred in the risk versus comparison interval for LAIV versus IIV.
For inpatient/ED asthma exacerbations, we ran the case-centered and case-centered 
difference-in-differences models for all children in the study, and separately for each asthma 
severity type. We performed a sensitivity analysis including all eligible children, but using a 
risk interval of 7–28 days and a comparison interval of 29–50 days.
To assess outpatient asthma exacerbations following LAIV, we used chart confirmed events 
and case-centered models including LAIV recipients only; for children with remote history 
of asthma only, we performed case-centered analyses separately for LAIV and IIV, and 
LAIV versus IIV using the difference-in-differences model. No adjustments were made for 
multiple comparisons.
3. Results
154,994 children had 387,633 influenza immunizations, of which 330,807 (85%) were IIV 
and 56,826 (15%) were LAIV (Table 1). Compared with IIV, children who received LAIV 
were more likely to be female and younger. Children getting LAIV were less likely to have 
“current or recent, persistent” asthma (25% versus 47% for IIV), and more likely to have 
“remote history” of asthma only (47% vs. 25%).
There was no clear temporal pattern of inpatient/ED asthma exacerbations in the 42 days 
following IIV or LAIV immunization (Fig. 1). Inpatient/ED events following LAIV were 
infrequent. The rates of inpatient/ED asthma exacerbations during the risk interval were 
substantially lower in children who received LAIV (19/100,0000 children) compared with 
those who received IIV (119/100,000 children), an observation seen in all subgroups except 
those with a remote history of asthma only (Table 2). Regardless of vaccine type, rates of 
asthma events were highest in children with current or recent, persistent asthma, and lowest 
in children with remote history of asthma only.
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Among children with remote history of asthma only, chart review confirmed outpatient 
asthma exacerbations for 403/572 (70%) events after IIV and 591/846 (70%) after LAIV 
(Supplemental Table 2). Confirmed outpatient asthma exacerbations rates were higher 
during the risk interval after IIV (257/100,000 children) than after LAIV (113/100,0000 
children; Table 2).
In contrast, IIV and LAIV recipients had similar rates of non-asthma related visits in the risk 
(15,486/100,000 [IIV] and 14,553/100,000 [LAIV]) and comparison intervals 
(14,399/100,000 [IIV] and 13,450/100,000[LAIV]).
Among IIV-vaccinated children, odds of an inpatient/ED asthma event occurring during the 
risk interval was not significantly different from that of the comparison interval (OR 0.97, 
95% Confidence Interval [CI]: 0.82–1.15), a finding which was consistent for each asthma 
severity subset (Table 3). Among LAIV-vaccinated children, odds of an inpatient/ED event 
occurring during the risk interval was lower than during the comparison interval (OR 0.39, 
95% CI: 0.17–0.90). Difference-in-differences analyses found that LAIV was associated 
with lower odds of asthma exacerbation compared to IIV (Ratio of ORs 0.40, 95% CI: 0.17–
0.95, p value: 0.04) among children with all asthma types and among those with current or 
recent, not persistent asthma (Ratio of OR 0.05, 95% CI: 0.01–0.58). Among children with 
all asthma types, changing the risk and comparison intervals to 7–28, and 29–50 days, 
respectively, minimally changed the OR for IIV (0.94, 95% CI: 0.82–1.07), LAIV (OR, 
0.36, 95% CI: 0.17–0.78) and LAIV versus IIV (0.38, 95% CI 0.17–0.84).
For children receiving LAIV, odds of an outpatient asthma exacerbation during the risk 
interval was lower than during the comparison interval (OR 0.75, 95% CI: 0.62–0.92; Table 
3). For children with remote history of asthma, the difference-in-differences model indicated 
no significant differences in asthma exacerbations between IIV and LAIV.
There was no significant difference in the odds of non-asthma related visits between LAIV 
and IIV recipients (Ratio of ORs 0.99, 95% CI: 0.94–1.04; Table 3). For other non-asthma-
related outcomes, the number of adverse events were low; incidence rates following IIV 
tended to be higher than those following LAIV (Table 4). Among these outcomes, only 
epistaxis had a significant difference, with LAIV versus IIV associated with decreased risk 
(Ratio of ORs 0.18, 95% CI: 0.04–0.82) – although the number of outcomes in the LAIV 
group was small (5 in the risk window, 16 in the comparison window).
4. Discussion
Evaluating a large population of children and adolescents with history of asthma, we found 
no evidence that LAIV was associated with increased risk of subsequent asthma 
exacerbations. On the contrary, our case-centered difference-in-differences analyses 
suggested that LAIV was associated with lower risk of inpatient/ED visits for asthma 
exacerbations.
We further found no evidence that LAIV increases the risk of outpatient visits for asthma 
exacerbations. In particular, we found no relationship between LAIV and outpatient asthma 
exacerbations for children with “remote history of asthma only”. This result is reassuring 
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since it has not been clear whether LAIV can be safely administered to these children. 
Despite the ACIP’s caution against it, children with a remote history of asthma represent 
asthmatics who would be most likely to inadvertently receive LAIV, related to either parents 
being unaware of cautions against LAIV or providers’ being unaware of asthma history. 
Together with the results from inpatient/ED setting, this study suggests that concerns about 
administering LAIV to children with asthma–especially those with current or recent, not 
persistent asthma or only a remote history of asthma – may not be warranted.
The observation that rates of asthma exacerbations were lower among LAIV recipients than 
among IIV recipients suggests that LAIV-vaccinated children differed from IIV-vaccinated 
children in their risk of subsequent exacerbations. Any residual confounding in our case-
centered difference-in-differences analysis would be related to timing of events following 
immunization, and could occur if clinicians (or parents) are able to predict who is going to 
have an imminent asthma exacerbation 1–14 days following vaccination versus having an 
exacerbation 29–42 days following vaccination. For example, a clinician might note that a 
patient with asthma has a cough or an upper respiratory infection (URI) and, being 
concerned about imminent asthma exacerbation, select IIV for that patient (or postpone 
LAIV vaccination until a later time); whereas for an identical patient without cough or URI 
they may have selected LAIV. Observations such as these at the time of vaccination may not 
be recorded in such a way as to allow for adjustment. While it is possible that residual 
confounding contributes to our finding that LAIV tends to be associated with decreased risk 
of asthma exacerbations, our results demonstrate that among children who actually received 
LAIV, asthma exacerbations were relatively rare and did not increase in the period following 
immunization. At the very least, LAIV appears safe for the type of children who have been 
receiving it through 2014.
Strengths of this study include KPNC’s influenza vaccination program which provides 
encouragement to KPNC’s membership to receive annual influenza vaccines. In the 2013–
2014 influenza season, approximately 50% of KPNC child members with prior diagnosis of 
asthma received an influenza vaccination. Although KPNC follows ACIP guidelines, 
clinicians can order vaccines outside of ACIP recommendations. Thus, KPNC has a 
significant population of children with pre-existing asthma diagnoses who received LAIV 
between 2007 and 2014. Our data also allowed us to re-evaluate asthma severity each year, 
which could therefore be treated as time-varying. Another strength is that we reviewed the 
charts of all post-LAIV outpatient asthma visits and post-IIV remote asthma visits, and 
found the majority of these were for asthma exacerbations rather than routine follow-up or 
management. It was reassuring to find similar asthma confirmation rates whether children 
received IIV or LAIV, and whether the event was during a risk or comparison interval.
In addition to potential residual confounding noted above, this study had limitations. We 
relied on diagnosis codes to identify asthma. Our modified HEDIS classification of asthma 
type likely included variations in severity within each type. In particular, our findings 
regarding children with current or recent, persistent asthma, may not apply to the smaller 
subset of children with very severe asthma. Further, despite the large number of children 
receiving LAIV, the number of inpatient/ED asthma exacerbations in this group was small. 
This is a reassuring finding, although the small number of events reduces the precision of 
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results. We also did not attempt to statistically account for persons who had an outcome in 
more than one season. However, this accounted for only 3.7% of inpatient/ED events, and 
1.2% of chart review confirmed outpatient asthma exacerbations; thus, any effect on the 
results is likely very small. Finally, KPNC providers – like those in some other health 
systems – have access to the full electronic medical record which likely affected their 
decisions regarding vaccine type. Our findings may not be as applicable in situations where 
providers do not have access to the full medical record.
In conclusion, among children and adolescents with a history of asthma, we found no 
evidence that those who received LAIV were more likely to have an asthma exacerbation 
than those who received IIV, and we found that incidence of such events following 
immunization with LAIV was relatively low regardless of asthma severity. Our findings 
indicate that use of LAIV in children ≥2 years old with asthma did not increase the risk of 
asthma exacerbations.
Supplementary Material
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Fig. 1. 
Rate of inpatient (IP) and Emergency Department (ED) asthma exacerbations by day 
following inactivated influenza vaccination (IIV) and live-attenuated influenza vaccination 
(LAIV).
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